Modification and validation of the Birmingham Vasculitis Activity Score (version 3).
BACKGROUND: Comprehensive multisystem clinical assessment using the Birmingham Vasculitis Activity score (BVAS) is widely used in therapeutic studies of systemic vasculitis. Extensive use suggested a need to revise the instrument. The previous version of BVAS has been revised, according to usage an...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2009
|
| _version_ | 1797076899854286848 |
|---|---|
| author | Mukhtyar, C Lee, R Brown, D Carruthers, D Dasgupta, B Dubey, S Flossmann, O Hall, C Hollywood, J Jayne, D Jones, R Lanyon, P Muir, A Scott, D Young, L Luqmani, R |
| author_facet | Mukhtyar, C Lee, R Brown, D Carruthers, D Dasgupta, B Dubey, S Flossmann, O Hall, C Hollywood, J Jayne, D Jones, R Lanyon, P Muir, A Scott, D Young, L Luqmani, R |
| author_sort | Mukhtyar, C |
| collection | OXFORD |
| description | BACKGROUND: Comprehensive multisystem clinical assessment using the Birmingham Vasculitis Activity score (BVAS) is widely used in therapeutic studies of systemic vasculitis. Extensive use suggested a need to revise the instrument. The previous version of BVAS has been revised, according to usage and reviewed by an expert committee. OBJECTIVE: To modify and validate version 3 of the BVAS in patients with systemic vasculitis. METHODS: The new version of BVAS was tested in a prospective cross-sectional study of patients with vasculitis. RESULTS: The number of items was reduced from 66 to 56. The subscores for new/worse disease and persistent disease were unified. In 313 patients with systemic vasculitis, BVAS(v.3) correlated with treatment decision (Spearman's r(s) = 0.66, 95% CI 0.59 to 0.72), BVAS1 of version 2 (r(s) = 0.94, 95% CI 0.92 to 0.96), BVAS2 of version 2 in patients with persistent disease (r(s) = 0.60, 95% CI 0.21 to 0.83), C-reactive protein levels (r(s) = 0.43, 95% CI 0.31 to 0.54), physician's global assessment (r(s) = 0.91, 95% CI 0.89 to 0.93) and vasculitis activity index (r(s) = 0.88, 95% CI 0.86 to 0.91). The intraclass correlation coefficients for reproducibility and repeatability were 0.96 (95% CI 0.95 to 0.97) and 0.96 (95% CI 0.92 to 0.97), respectively. In 39 patients assessed at diagnosis and again at 3 months, the BVAS(v.3) fell by 17 (95% CI 15 to 19) units (p<0.001, paired t test). CONCLUSION: BVAS(v.3) demonstrates convergence with BVAS(v.2), treatment decision, physician global assessment of disease activity, vasculitis activity index and C-reactive protein. It is repeatable, reproducible and sensitive to change. The new version of BVAS is validated for assessment of systemic vasculitis. |
| first_indexed | 2024-03-07T00:10:09Z |
| format | Journal article |
| id | oxford-uuid:78f6aa30-8977-4631-b357-bb5d8a6e128e |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:10:09Z |
| publishDate | 2009 |
| record_format | dspace |
| spelling | oxford-uuid:78f6aa30-8977-4631-b357-bb5d8a6e128e2022-03-26T20:34:11ZModification and validation of the Birmingham Vasculitis Activity Score (version 3).Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:78f6aa30-8977-4631-b357-bb5d8a6e128eEnglishSymplectic Elements at Oxford2009Mukhtyar, CLee, RBrown, DCarruthers, DDasgupta, BDubey, SFlossmann, OHall, CHollywood, JJayne, DJones, RLanyon, PMuir, AScott, DYoung, LLuqmani, R BACKGROUND: Comprehensive multisystem clinical assessment using the Birmingham Vasculitis Activity score (BVAS) is widely used in therapeutic studies of systemic vasculitis. Extensive use suggested a need to revise the instrument. The previous version of BVAS has been revised, according to usage and reviewed by an expert committee. OBJECTIVE: To modify and validate version 3 of the BVAS in patients with systemic vasculitis. METHODS: The new version of BVAS was tested in a prospective cross-sectional study of patients with vasculitis. RESULTS: The number of items was reduced from 66 to 56. The subscores for new/worse disease and persistent disease were unified. In 313 patients with systemic vasculitis, BVAS(v.3) correlated with treatment decision (Spearman's r(s) = 0.66, 95% CI 0.59 to 0.72), BVAS1 of version 2 (r(s) = 0.94, 95% CI 0.92 to 0.96), BVAS2 of version 2 in patients with persistent disease (r(s) = 0.60, 95% CI 0.21 to 0.83), C-reactive protein levels (r(s) = 0.43, 95% CI 0.31 to 0.54), physician's global assessment (r(s) = 0.91, 95% CI 0.89 to 0.93) and vasculitis activity index (r(s) = 0.88, 95% CI 0.86 to 0.91). The intraclass correlation coefficients for reproducibility and repeatability were 0.96 (95% CI 0.95 to 0.97) and 0.96 (95% CI 0.92 to 0.97), respectively. In 39 patients assessed at diagnosis and again at 3 months, the BVAS(v.3) fell by 17 (95% CI 15 to 19) units (p<0.001, paired t test). CONCLUSION: BVAS(v.3) demonstrates convergence with BVAS(v.2), treatment decision, physician global assessment of disease activity, vasculitis activity index and C-reactive protein. It is repeatable, reproducible and sensitive to change. The new version of BVAS is validated for assessment of systemic vasculitis. |
| spellingShingle | Mukhtyar, C Lee, R Brown, D Carruthers, D Dasgupta, B Dubey, S Flossmann, O Hall, C Hollywood, J Jayne, D Jones, R Lanyon, P Muir, A Scott, D Young, L Luqmani, R Modification and validation of the Birmingham Vasculitis Activity Score (version 3). |
| title | Modification and validation of the Birmingham Vasculitis Activity Score (version 3). |
| title_full | Modification and validation of the Birmingham Vasculitis Activity Score (version 3). |
| title_fullStr | Modification and validation of the Birmingham Vasculitis Activity Score (version 3). |
| title_full_unstemmed | Modification and validation of the Birmingham Vasculitis Activity Score (version 3). |
| title_short | Modification and validation of the Birmingham Vasculitis Activity Score (version 3). |
| title_sort | modification and validation of the birmingham vasculitis activity score version 3 |
| work_keys_str_mv | AT mukhtyarc modificationandvalidationofthebirminghamvasculitisactivityscoreversion3 AT leer modificationandvalidationofthebirminghamvasculitisactivityscoreversion3 AT brownd modificationandvalidationofthebirminghamvasculitisactivityscoreversion3 AT carruthersd modificationandvalidationofthebirminghamvasculitisactivityscoreversion3 AT dasguptab modificationandvalidationofthebirminghamvasculitisactivityscoreversion3 AT dubeys modificationandvalidationofthebirminghamvasculitisactivityscoreversion3 AT flossmanno modificationandvalidationofthebirminghamvasculitisactivityscoreversion3 AT hallc modificationandvalidationofthebirminghamvasculitisactivityscoreversion3 AT hollywoodj modificationandvalidationofthebirminghamvasculitisactivityscoreversion3 AT jayned modificationandvalidationofthebirminghamvasculitisactivityscoreversion3 AT jonesr modificationandvalidationofthebirminghamvasculitisactivityscoreversion3 AT lanyonp modificationandvalidationofthebirminghamvasculitisactivityscoreversion3 AT muira modificationandvalidationofthebirminghamvasculitisactivityscoreversion3 AT scottd modificationandvalidationofthebirminghamvasculitisactivityscoreversion3 AT youngl modificationandvalidationofthebirminghamvasculitisactivityscoreversion3 AT luqmanir modificationandvalidationofthebirminghamvasculitisactivityscoreversion3 |